65 patents
Page 3 of 4
Utility
Crystalline Substituted Pyrazines As PGI2 Receptor Agonists
22 Apr 21
Toshio FUJIWARA
Filed: 28 Dec 20
Utility
Crystalline substituted pyrazines as PGI2 receptor agonists
2 Feb 21
Toshio Fujiwara
Filed: 27 Sep 18
Utility
Crystal of Compound Having Jak-inhibiting Activity
21 Jan 21
Fumi HIGUCHI
Filed: 29 Sep 20
Utility
Granular Composition, Production Method for Granular Composition, and Dissolution Property Improvement Method for Granular Composition
23 Dec 20
Toshinori TANAKA, Rie YAMADA
Filed: 19 Feb 19
Utility
Antisense nucleic acids
21 Dec 20
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
Filed: 9 May 19
Utility
Antisense nucleic acids
30 Nov 20
The present invention provides an oligomer which allows exon 45 skipping in the human dystrophin gene.
Yukiko Enya, Yuichiro Tone, Shin'ichi Takeda, Yoshitsugu Aoki
Filed: 15 Oct 18
Utility
Controlled-release Preparation
18 Nov 20
Shouji FURUTA, Naoto HATTORI
Filed: 14 Nov 18
Utility
Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide
9 Nov 20
A stabilized solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is provided, namely, a solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and D-mannitol having a specific surface area of 1.0 m2/g or less.
Shouji Furuta, Hironori Mukai
Filed: 24 Jul 18
Utility
Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
2 Nov 20
A stabilized solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is provided, namely, a solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and D-mannitol having a specific surface area of 1.0 m2/g or less.
Shouji Furuta, Hironori Mukai
Filed: 30 Nov 16
Utility
Crystal of compound having JAK-inhibiting activity
2 Nov 20
Fumi Higuchi
Filed: 27 Feb 17
Utility
Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide
21 Sep 20
A stabilized solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide is provided, namely, a solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and D-mannitol having a specific surface area of 1.0 m2/g or less.
Shouji Furuta, Hironori Mukai
Filed: 24 Jul 18
Utility
Antisense nucleic acids
21 Sep 20
The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency.
Naoki Watanabe, Haruna Seo, Shin'ichi Takeda, Tetsuya Nagata
Filed: 11 Jan 18
Utility
Crystal
15 Jul 20
Toshio FUJIWARA
Filed: 26 Sep 18
Utility
Crystals
15 Jul 20
A main object of the present invention is to provide new crystals of (S)-N2-[1-(4-fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N6-(pyrazin-2-yl)pyridine-2,6-diamine maleate (hereinafter, referred to as “compound A”).
Toshio FUJIWARA, Joanna BIS, Senthil Kumar Kusalakumari SUKUMAR
Filed: 26 Sep 18
Utility
Antisense nucleic acids
15 Jun 20
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
Filed: 16 Dec 19
Utility
Antisense nucleic acids
25 May 20
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
Filed: 11 Dec 19
Utility
Antisense Nucleic Acids
13 May 20
Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene.
Tatsushi WAKAYAMA, Haruna SEO, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 10 Jun 19
Utility
Antisense nucleic acids
11 May 20
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki Watanabe, Youhei Satou, Shin'ichi Takeda, Tetsuya Nagata
Filed: 23 Jun 19
Utility
Antisense Nucleic Acid for Treating Amyotrophy
22 Apr 20
There has been a demand for a novel antisense nucleic acid or the like capable of inhibiting myostatin at the mRNA level.
Shinichiro NAKAGAWA
Filed: 19 Dec 19
Utility
Antisense Nucleic Acids
15 Apr 20
The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene.
Naoki WATANABE, Youhei SATOU, Shin'ichi TAKEDA, Tetsuya NAGATA
Filed: 9 May 19